A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and
effective for patients who are current injection drug users or receiving opiate substitution
therapy and who are responding well to treatment early on.